Hervé Hoppenot, Incyte CEO

In­cyte se­cures sec­ond FDA ap­proval for bile duct can­cer drug in mu­tat­ed can­cer type

In­cyte nabbed its sec­ond ap­proval from fed­er­al reg­u­la­tors for can­cer drug pemi­ga­tinib, brand­ed as Pe­mazyre — as the po­ten­tial for even more in­di­ca­tions await.

The com­pa­ny, head­ed by CEO Hervé Hop­penot, put out word be­fore the mar­ket opened on Fri­day that the FDA ap­proved Pe­mazyre un­der pri­or­i­ty re­view for re­lapsed or re­frac­to­ry myeloid/lym­phoid neo­plasms (MLNs) with FGFR1 re­arrange­ment. The drug, an FGFR1/2/3 in­hibitor, was orig­i­nal­ly ap­proved back in 2020 for cholan­gio­car­ci­no­ma, al­so known as bile duct can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.